# Executive Director, Asset Team Lead at Recursion

- Company: Recursion
- What the company does: Dive into Recursion's innovative approach to decoding biology. Join our mission & explore what AI drug discovery companies can do. Contact us today! Backed by SoftBank VF, CRV and Felicis.
- Company website: https://recursion.com/
- Type: Startups (AI role)
- Level: Principal and up
- Location: Remote Opportunity - United States
- Work setup: Remote
- Posted: 2026-09-21
- Apply by: 2026-11-05
- Apply: https://job-boards.greenhouse.io/recursionpharmaceuticals/jobs/8221194
- Page: https://www.1752.vc/careers/jobs/recursion-executive-director-asset-team-lead/

## About the role

As the Recursion clinical asset pipeline continues to mature through key inflection points, the advancing assets require leaders who can translate scientific complexity into strategic clarity. In the role of Executive Director, Asset Team Lead, you will drive the strategic positioning of assets, ensuring that decisioning is grounded in competitive reality, differentiated by Recursion OS insights, and built to move with urgency for patient benefit.

## What they're looking for

- A PhD in life sciences or related scientific discipline with deep expertise in drug discovery & development required
- 10+ years of biotech/pharma experience with a proven track record of asset-level strategic leadership, advancing programs through clinical stage-gates with demonstrable impact on portfolio value
- Deep expertise in the development of small molecule therapeutics for oncology and immunology/inflammation required, expertise in rare disease a bonus
- Experience leveraging computational approaches and data-driven platforms to sharpen asset strategy and clinical decision-making
- Proven ability to build and articulate the strategic and competitive case for clinical assets – integrating mechanistic differentiation, competitive dynamics, regulatory and market considerations
- Strong financial acumen, able to engage credibly on cross-functional resourcing, asset valuation, and portfolio trade-offs

Tags: Development